1. Evaluating the reliability of hair analysis in monitoring the compliance of ADHD patients under treatment with Lisdexamphetamine
- Author
-
Marianne Haedener, Michael Liebrenz, Dominique Eich, Anna Buadze, Wolfgang Weinmann, Thomas Wuethrich, University of Zurich, and Buadze, Anna
- Subjects
Male ,Physiology ,Urine ,030226 pharmacology & pharmacy ,01 natural sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Medical Conditions ,Tandem Mass Spectrometry ,Medicine and Health Sciences ,Ambulatory Care ,Outpatient clinic ,610 Medicine & health ,media_common ,Multidisciplinary ,medicine.diagnostic_test ,Pharmaceutics ,Hair analysis ,Therapeutic Drug Monitoring ,Middle Aged ,Adjustment of Dosage at Steady State ,Clinical Laboratory Sciences ,Body Fluids ,Treatment Outcome ,Neurology ,Medicine ,Female ,Anatomy ,Integumentary System ,Drug Monitoring ,medicine.drug ,Research Article ,Drug ,Adult ,medicine.medical_specialty ,Science ,media_common.quotation_subject ,Neuropsychiatric Disorders ,Medication Adherence ,03 medical and health sciences ,Young Adult ,Pharmacotherapy ,Dose Prediction Methods ,Drug Therapy ,Developmental Neuroscience ,Diagnostic Medicine ,Internal medicine ,Mental Health and Psychiatry ,medicine ,Humans ,Lisdexamfetamine Dimesylate ,Amphetamine ,Forensics ,Creatinine ,1000 Multidisciplinary ,Dose-Response Relationship, Drug ,business.industry ,010401 analytical chemistry ,Biology and Life Sciences ,Reproducibility of Results ,0104 chemical sciences ,chemistry ,Hair Analysis ,Therapeutic drug monitoring ,Neurodevelopmental Disorders ,Attention Deficit Disorder with Hyperactivity ,10054 Clinic for Psychiatry, Psychotherapy, and Psychosomatics ,Adhd ,Central Nervous System Stimulants ,business ,Mental Health Therapies ,Hair ,Neuroscience ,Chromatography, Liquid - Abstract
Considering the high clinical and forensic relevance of pharmaco-adherence during lisdexamphetamine (LDX) treatment for attention-deficit/hyperactivity disorder (ADHD), the aim here was to evaluate hair analysis as a tool for monitoring compliance in patients currently undergoing long term treatment with LDX, by detecting possible interruptions of medication intake or changes in dosage. For this purpose, a total of 24 patients from an outpatient clinic for ADHD were recruited. Hair and urine samples were taken after three consecutive therapy sessions over a 7-month period and analyzed for amphetamine (AMP) enantiomers and other drugs, using chiral and achiral liquid chromatography-tandem mass spectrometry (LC-MS/MS). Participants also provided information on the condition of their hair, the consumption of illegal psychotropic substances and the regularity of taking LDX. Two participants withdrew from the study early. Urine analyses were positive for D-AMP in all urine samples and therapy sessions, except in two patients who did not take LDX on a daily basis. D-AMP was detected in all hair samples; however, no correlation was found between prescribed dose/day and D-AMP concentrations in proximal hair segments. Qualitative interpretation of hair analysis showed that 18 of the 22 study completers were compliant concerning the intake of LDX without additional consumption of illegal D,L-AMP. Analysis of urine taken during the therapy sessions showed no correlation between D-AMP concentrations and prescribed dosage, with or without normalization for creatinine. In conclusion, chiral LC-MS/MS hair analysis might represent a non-invasive way to confirm LDX use within the approximate period covered by the hair segment tested, but it does not allow for quantitative therapeutic drug monitoring because of interindividual variability of concentrations in hair. Drug concentrations in hair at different stages of long-term treatment should thus be interpreted with caution by clinicians and forensic experts alike when making assessments of treatment adherence.
- Published
- 2021